We use cookies to ensure that we give you the best experience on our website. By continuing to browse this site, you are agreeing to our use of cookies as set out in our cookie notice. Please read our cookie notice for more information on the cookies we use and how to delete or block the use of cookies.
FEIBA is an Anti-Inhibitor Coagulant Complex indicated for use in hemophilia A and B patients with inhibitors for:
Control and prevention of bleeding episodes
Detailed Important Risk Information
WARNING: EMBOLIC AND THROMBOTIC EVENTS
Thromboembolic events have been reported during post-marketing surveillance following infusion of FEIBA,
Indications for Feiba
FEIBA is an Anti-Inhibitor Coagulant Complex indicated for use in hemophilia A and B patients with inhibitors for:
Control and prevention of bleeding episodes
Perioperative management
Routine prophylaxis to prevent or reduce the frequency of bleeding episodes.
FEIBA is not indicated for the treatment of bleeding episodes resulting from...
Detailed Important Risk Information
WARNING: EMBOLIC AND THROMBOTIC EVENTS
Thromboembolic events have been reported during post-marketing surveillance following infusion of FEIBA, particularly following the administration of high doses (above 200 units per kg per day) and/or in patients with thrombotic risk factors.
Monitor patients receiving FEIBA for signs and symptoms of thromboembolic events.
;
You are now navigating away from feiba.com
By clicking "OK" below you will be taken to a website that may contain links or references to other websites to which our Privacy Notice may not apply. We encourage you to read the Privacy Policy of every website you visit.
![FEIBA [Anti-Inhibitor Coagulant Complex]. Please see Detailed Important Risk Information, including BOXED WARNING on Embolic and Thrombotic events and full PI.](/us/content/dist/images/Hcp/logo.webp){kind=logo}
